Essais liés8clinical trials
VillePlymouthlocalisation
PaysUnited Kingdomlocalisation
SourcelocaleCSV/MySQL

Informations

centre

Synchronisé depuis ClinicalTrials.gov — NCT05660967

Ouvrir le site du centre

Essais cliniques associés

8
MoléculeIndication / populationPhaseNCTTitreStatut
Survodutide Maladie coronarienne Phase 3 NCT07850063 ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease NOT_YET_RECRUITING
Colchicine 0.5 MG Oral Tablet Maladie coronarienne Phase 3 NCT04774159 LEADER-PAD — Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk RECRUITING
Epcoritamab SEP Phase 2 NCT05660967 EPCORE DLBCL-3 — Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma TERMINATED
Prasinezumab Parkinson Phase 2 NCT04777331 PADOVA — A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease ACTIVE_NOT_RECRUITING
Tacabrutideg Cancer Phase 1/2 NCT05006716 CaDAnCe-101 — A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies RECRUITING
Obinutuzumab Cancer Phase 3 NCT06084936 GLOBRYTE — A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma RECRUITING
Ocrelizumab SEP Phase 3 NCT04544436 MUSETTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) ACTIVE_NOT_RECRUITING
Ocrelizumab SEP Phase 3 NCT04548999 GAVOTTE — A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) ACTIVE_NOT_RECRUITING